• Ms.Amy Lu
    Tel: 027-84306245

  • Mobile:
  • Tel:027-84306245
  • Fax:
  • URL:http://www.wondapharm.com
  • Province/state:Hubei
  • City:Wuhan
  • Street:Wuhan Private Science and Technology Park , Wuhan, China
  • MaxCard:
Home > Products >  Top quality 99% Ledipasvir powder GS-5885

Top quality 99% Ledipasvir powder GS-5885 CAS NO.1441674-54-9

  • Min.Order: 10 Gram
  • Payment Terms: T/T,MoneyGram
  • Product Details

Keywords

  • Ledipasvir
  • Ledipasvir powder
  • GS-5885

Quick Details

  • ProName: Top quality 99% Ledipasvir powder GS-5...
  • CasNo: 1441674-54-9
  • Molecular Formula: C49H54F2N8O6.C3H6O
  • Appearance: white powder
  • DeliveryTime: immediately
  • PackAge: aluminum foil bag
  • Port: HK, Shanghai, Shenzhen
  • ProductionCapacity: 100 Kilogram/Month
  • Purity: 99%
  • Storage: cool and dry place
  • Transportation: email: wonda-chem@outlook.com
  • LimitNum: 10 Gram

Superiority

1.high quality:

quality is life. quality is the most important element for all goods. we have a lab doing research in wuhan china. hplc and nmr is available if needed.

2.reasonable price:

we provide high quality products with competitive price in china. all customers are welcomed to send us inquiries and get quotation.

3.low moq:

no worry about the low moq, our moq is 1 gram or even lower.

4.good service.

fast response. we promise to reply within 24 hours including holidays and send quotation sheet and other documents within 48 hours.

5. fast shipping and secure courier.

we promise to send out products and provide tracking number within 3 working days. and we send via different couriers based on different destination countries. we usually use nl post, hk post, germany post, eub, etk, etc.

 

Details

Top quality 99% Ledipasvir powder GS-5885 CAS 1441674-54-9 

 

What is Ledipasvir

Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C.The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.

Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion, a hepatitis C virus protein.

 

 

Packing and shipping

 

 

 

 

 

 

 

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog